aceArtificial intelligence in drug discovery - what it is, where we stand and the path forward
Artificial intelligence (AI) in drug discovery has attracted increasing interest over the past decade. It is now time for a critical review of progress in the field: where did we advance - and where are we yet to see impact - when it comes to what matters in drug discovery, which is to deliver safer and more efficacious medicines to patients faster? Although a wide variety of AI methods have been developed, applied and benchmarked, evidence of their clinically relevant impact is, so far, disappointingly limited.…
AI methods in drug discovery have so far shown disappointingly limited clinically relevant impact on delivering safer and more efficacious medicines to patients faster.
Translational relevance remains limited by model development choices and operationalization challenges, including insufficient focus on clinical translation and time required to scale systems for users.
Evidence
- Peer-reviewedNature Reviews Drug Discovery2026-08-07
How should this claim be treated?
Truvace Impact Record TRV-2026-0733, v1: “Artificial intelligence in drug discovery - what it is, where we stand and the path forward.” Truvace, 2026-08-11. /record/TRV-2026-0733 (accessed at citation time). sha256 b31d509eda1518d0…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-0733 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.